. | . |
Delivering next-gen biomanufacturing capability by Staff Writers Washington DC (SPX) Aug 26, 2021
Slow production methods and reliance on a global supply chain currently limit DoD access to critical proteins such as medical countermeasures (MCMs) (i.e. antibodies, vaccines, and clotting factors), diagnostic components, and key enzymes for producing nucleic acids. State-of-the-art protein-based MCM production calls for massive centralized infrastructure and complex pipelines that require lengthy cellular engineering, sufficient growth of cells, and intensive purification and quality control. Current response times are several months for production, with additional time needed for dispersing MCMs to vulnerable populations. Distributed manufacturing paradigms may transform these timelines into those relevant to DoD response, especially in denied, degraded, or disrupted operational environments. To address these challenges, the Reimagining Protein Manufacturing (RPM) program aims to establish the foundational technologies needed for fully distributed, on-demand manufacturing of biologics-based MCMs and their associated raw materials. DARPA programs, such as Make-It, Nucleic Acids on Demand (NOW), and Battlefield Medicine, have invested in distributed manufacturing of pharmaceuticals and nucleic acids. Continuing DARPA's role in challenging manufacturing paradigms, RPM focuses on the complex process of protein production, and will attend to the biochemistry challenges associated with producing bioactive proteins at high yields with short lead times. "As was reinforced during the COVID-19 pandemic, many crucial building blocks for proteins, therapeutics and diagnostics are currently manufactured outside of the United States," stated Dr. Amy Jenkins, RPM program manager. "The RPM program will serve warfighters by strengthening the U.S. biomanufacturing supply chain and providing new methods for timely development of protein-based therapeutics and enzymes." The 50-month RPM program will address two technical areas (TAs). TA1 "Production Yield and Time" focuses on protein synthesis technologies for near-immediate synthesis of proteins at high yields. TA2 "Post-Translational Modifications" seeks novel protein production approaches to add PTMs in a controlled manner to ensure the final product is bioactive and of high quality. The U.S. Government will utilize Independent Validation and Verification (IV&V) partners throughout the program to assess the function, stability, and composition of the proteins produced through a series of field recognized analytical techniques. "If successful, RPM will result in novel protein production technologies not previously deployed," added Jenkins. Additional details of the program schedule and metrics are available in the broad agency announcement here.
AFRL showcases new precision effects capability Eglin AFB FL (AFNS) Aug 19, 2021 The Air Force Research Laboratory concluded its Dialable Effects Munition demonstration program during a test of the experimental weapon July 28. The DEM, an Office of the Secretary of Defense-funded Joint Capability Technology Demonstration, aims to mature, demonstrate and transition technologies that enable a weapon's effects to be tailored dynamically in flight. This new capability will give the Department of the Air Force the ability to prosecute targets more effectively in high-end fights, wh ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |